Vaxart Inc - Company Profile
Powered by 
All the sales intelligence you need on Vaxart Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Vaxart Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Vaxart Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Vaxart Inc (Vaxart) is a clinical-stage biotechnology company which focuses on developing oral recombinant vaccines. It is focused on the development of oral recombinant vaccines using its proprietary Vector-Adjuvant-Antigen Standardized Technology (VAAST) platform. The company's main activities involve the research and development of vaccine candidates targeting a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. Additionally, Vaxart is developing a therapeutic immune-oncology vaccine targeting cervical cancer and dysplasia caused by human papillomavirus (HPV). The company's oral tablet vaccine candidates are designed to generate broad and durable immune responses, including systemic, mucosal, and T cell responses, which may enhance protection against infectious diseases and have potential clinical benefits for certain cancers and chronic viral infections. Vaxart is headquartered in San Francisco, California, the US.
Headquarters
United States of America
Address
170 Harbor Way, Suite 300, South San Francisco, California, 94080
Website
www.vaxart.com
Telephone
1 650 5503500
No of Employees
65
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VXRT (OTC)
Revenue (2024)
$237.3M
726.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
124.4%
(2024 vs 2023)
Market Cap*
$137.9M
Net Profit Margin (2024)
XYZ
103.0%
(2024 vs 2023)
* As of and is in US$
Vaxart Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Royalty Product: | VAAST Platform |
| Relenza- Influenza | |
| Inavir- Influenza | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In November, the company entered into an license and collaboration agreement with Dynavax Technologies Corp for its investigational oral COVID-19 vaccine program and clinical development and commercialization following Phase 2b clinical development. |
| 2022 | Contracts/Agreements | In June, the company entered into an agreement with hVIVO, to develop World’s First Human Omicron Challenge Model. |
| 2021 | Contracts/Agreements | In December, the company entered into an agreement with Kindred Bioscience to acquire KindredBio’s manufacturing equipment and sublease of its GMP manufacturing facility in Burlingame, California, the US. |
Competitor Comparison
| Key Parameters | Vaxart Inc | Merck & Co Inc | Pfizer Inc | Novartis AG | Sanofi |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Switzerland | France |
| City | South San Francisco | Rahway | New York City | Basel | Paris |
| State/Province | California | New Jersey | New York | Basel-Stadt | Ile-de-France |
| No. of Employees | 65 | 75,000 | 75,000 | 75,267 | 76,493 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Steven Lo | Chief Executive Officer; Director; President | Executive Board | 2024 | 59 |
| Jeroen Grasman | Chief Financial Officer | Senior Management | 2025 | - |
| James F. Cummings, M.D. | Chief Medical Officer | Senior Management | 2021 | 60 |
| Sean Tucker, Ph.D. | Chief Scientific Officer; Senior Vice President | Senior Management | 2010 | 58 |
| Edward B. Berg | General Counsel; Senior Vice President | Senior Management | 2022 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer